DHR vs RVTY vs BIO Stock Comparison

Danaher, Revvity and Bio-Rad Laboratories Prices as of Nov 13, 2026 Peers: Industry group
DHR Danaher Corp /De/
$233.03 +3.7% 1M +5.3% 1Y
Market cap
$162.01B
P/E
37.4x
Revenue (TTM)
$25.61B
Div. yield
–
Life Sciences Tools Healthcare
5 wins
RVTY Revvity, Inc.
$154.52 +1.5% 1M +65.4% 1Y
Market cap
$16.64B
P/E
65.7x
Revenue (TTM)
$2.94B
Div. yield
0.00%
Life Sciences Tools Healthcare
3 wins

Head to Head

11 decided of 12

Danaher leads on 5 of the 12 questions below (Danaher 5, Bio-Rad Laboratories 3, Revvity 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionDHRRVTYBIOLeader
Larger companyMarket capitalisation $162.01B $16.64B $9.64B DHR
Cheaper on earningsLower P/E, profitable companies only 37.4x 65.7x 9.4x BIO
Cheaper on forward earningsLower price / next fiscal year consensus EPS 25.6x 29.9x 36.0x DHR
Faster revenue growthRevenue growth, trailing twelve months +5.5% +4.6% +1.4% DHR
More profitableNet margin, trailing twelve months 16.9% 8.6% 39.5% BIO
Better return on capitalReturn on invested capital 5.8% 3.3% -0.6% DHR
Less leveragedLower net debt / EBITDA 2.6x 2.6x — RVTY
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +5.3% +65.4% +15.5% RVTY
Better 5-year returnAnnualised price return, 5 years -5.2%/yr -3.4%/yr -13.5%/yr RVTY
Less volatileAnnualised volatility, 1 year 31.0% 41.2% 36.5% DHR
Higher overall scoreMean of the five percentile scores vs peers 60/100 61/100 70/100 BIO

Percentile Scorecard

DHRRVTYBIO

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisDHRRVTYBIO
Valuation 69 #76 of 243 72 #70 of 243 85 #38 of 243
Growth 25 #172 of 228 38 #141 of 228 48 #120 of 228
Profitability 86 #32 of 222 81 #43 of 222 70 #67 of 222
Financial Health 47 #133 of 248 56 #110 of 248 66 #85 of 248
Shareholder Returns 73 #44 of 158 56 #70 of 158 80 #32 of 158
Overall 60 61 70
  • DHR ranked among 252 companies in Medical Devices and Diagnostics
  • RVTY ranked among 252 companies in Medical Devices and Diagnostics
  • BIO ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodDHRRVTYBIOSPY
1 month +3.7%+1.5%+1.0% -2.0%
3 months +15.1%+32.2%+2.8% -2.8%
6 months +43.9%+64.4%+47.9% +2.0%
Year to date +1.8%+59.7%+20.8% +10.6%
1 year +5.3%+65.4%+15.5% +12.2%
3 years +14.5%+75.9%+19.1% +68.1%
3 years, per year +4.6%+20.7%+6.0% +18.9%
5 years -23.4%-15.8%-51.6% +61.4%
5 years, per year -5.2%-3.4%-13.5% +10.1%
10 years +187.9%+203.6%+119.6% +248.5%
10 years, per year +11.2%+11.7%+8.2% +13.3%

Risk

MeasureDHRRVTYBIOSPY
Volatility, 1Y 31.0%41.2%36.5% 13.6%
Downside volatility, 1Y 32.4%37.1%35.6% 13.9%
Beta vs S&P 500, 1Y 0.551.220.75 1.00
Return / volatility, 1Y 0.171.590.43 0.90
Max drawdown, 5Y -50.8%-59.2%-72.2% -25.4%
From 52-week high -3.7%-6.8%-6.2% -3.2%
52-week high $242.05$165.78$390.34 $779.14
52-week low $161.91$82.26$241.71 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleDHRRVTYBIO
P/E now vs peer median 37.9xmedian 26.5x 68.1xmedian 26.5x 9.6xmedian 26.5x
P/S now vs peer median 6.4xmedian 2.7x 5.9xmedian 2.7x 3.8xmedian 2.7x
EV/EBITDA now vs peer median 23.5xmedian 18.4x 24.4xmedian 18.4x —median 18.4x
P/FCF now vs peer median 28.6xmedian 25.4x 28.7xmedian 25.4x 29.9xmedian 25.4x
P/B now vs peer median 3.1xmedian 2.5x 2.4xmedian 2.5x 1.3xmedian 2.5x
PEG now vs peer median -4.72median 0.98 -2.46median 0.98 0.09median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsDHRRVTYBIO
Revenue $25.61B $2.94B $2.59B
Gross profit $15.01B $1.64B $1.33B
Operating income $5.22B $372.09M -$61.90M
Net income $4.33B $253.20M $1.02B
Free cash flow $5.73B $601.13M $329.10M
R&D $1.67B $213.15M $265.80M
EPS (diluted) $6.13 $2.26 $37.96
Cash & equivalents $5.68B $592.80M $465.30M
Total debt $26.48B $2.63B $1.20B
Shares (diluted) 706.80M 111.83M 26.95M
Enterprise value $141.66B $13.24B $3.25B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricDHRRVTYBIO
P/E 37.9x 68.1x 9.6x
P/FCF 28.6x 28.7x 29.9x
P/Operating cash flow 23.9x 25.9x 21.0x
P/S 6.4x 5.9x 3.8x
P/B 3.1x 2.4x 1.3x
P/Tangible book 5.0x 3.4x 1.3x
EV/EBITDA 23.5x 24.4x –
EV/EBIT 35.4x 51.8x -151.6x
EV/Revenue 7.2x 6.6x 3.6x
EV/FCF 32.3x 32.1x 28.5x
EV/Operating cash flow 26.9x 28.9x 20.1x
PEG (3Y EPS CAGR) -4.72 -2.46 0.09

Growth

14 metrics
MetricDHRRVTYBIO
Revenue growth (1Y) 5.5% 4.6% 1.4%
Revenue CAGR (3Y) 1.3% 1.7% -1.6%
Gross profit growth (1Y) 3.9% 5.8% -0.6%
Gross profit CAGR (3Y) 1.2% 1.2% -3.0%
Operating income growth (1Y) 13.1% 2.3% -127.6%
Operating income CAGR (3Y) -3.8% 1.0% -29.5%
Net income growth (1Y) 23.6% 6.6% 251.3%
Net income CAGR (3Y) -9.9% -30.1% 103.5%
EPS growth (1Y) 24.8% 10.1% 251.2%
EPS CAGR (3Y) -8.0% -27.6% 107.7%
Operating cash flow growth (1Y) 8.6% 14.4% -4.8%
Operating cash flow CAGR (3Y) -5.3% 49.3% 7.8%
Free cash flow growth (1Y) 14.2% 19.1% -2.3%
Free cash flow CAGR (3Y) -5.8% 44.7% 13.6%

Profitability

14 metrics
MetricDHRRVTYBIO
Gross margin 58.6% 55.9% 51.3%
EBITDA margin 30.7% 26.8% –
Operating margin 20.4% 12.6% -2.4%
Pretax margin 18.8% 9.6% 50.9%
Net margin 16.9% 8.6% 39.5%
FCF margin 22.4% 20.4% 12.7%
Operating cash flow margin 26.8% 22.7% 18.1%
Return on equity 8.2% 3.5% 13.8%
Return on assets 4.7% 2.2% 9.7%
Return on invested capital 5.8% 3.3% -0.6%
Return on capital employed 6.2% 3.4% -0.6%
Asset turnover 0.3x 0.2x 0.2x
Cash conversion (OCF / net income) 1.6x 2.6x 0.5x
Stock comp / revenue 1.3% 0.9% 2.4%

Financial Health

11 metrics
MetricDHRRVTYBIO
Debt / assets 28.4% 22.9% 11.2%
Debt / equity 0.5x 0.4x 0.2x
Net debt / EBITDA 2.6x 2.6x –
Debt / FCF 4.6x 4.4x 3.7x
Liabilities / assets 42.5% 36.7% 29.5%
Equity / assets 57.5% 63.3% 70.5%
Interest coverage 14.5x 4.2x -1.3x
Current ratio 1.6x 2.7x 3.2x
Quick ratio 1.1x 1.9x 2.2x
Cash ratio 0.6x 0.8x 1.7x
Altman Z-score 3.75 3.69 3.41

Shareholder Returns

7 metrics
MetricDHRRVTYBIO
Dividend yield 0.7% 0.2% –
Net buyback yield 0.5% 1.5% 0.7%
Shareholder yield 1.1% 1.7% 0.7%
Payout ratio (earnings) – 12.4% –
Payout ratio (FCF) – 5.2% –
Dividend growth (1Y) – -5.9% –
Dividend CAGR (3Y) – -6.2% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusDHRRVTYBIO
Forward P/E 25.6xFY2026 29.9xFY2026 36.0xFY2026
EPS, next fiscal year $9.12FY2026 $5.16FY2026 $10.18FY2026
EPS growth, next FY +16.9%FY2026 +2.0%FY2026 +2.6%FY2026
EPS growth, the year after +7.9% +11.0% -0.2%
Revenue, next fiscal year $27.01BFY2026 $3.00BFY2026 $2.69BFY2026
Revenue growth, next FY +9.9%FY2026 +4.8%FY2026 +4.2%FY2026
Revenue growth, the year after -1.9% -2.0% -7.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersDHRRVTYBIO
Held by institutions 81.9% 100.0% 89.5%
Institutions holding 2,121 547 405
Change in shares held, QoQ +1.1% -1.3% -2.9%
Institutions buying 841 303 177
Institutions selling 1,016 161 157
Buyers to sellers 0.83 1.88 1.13

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

DHRRVTYBIO
DHR 1.00 0.53 0.52
RVTY 0.53 1.00 0.54
BIO 0.52 0.54 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, DHR, RVTY and BIO?

Danaher (DHR) is the largest by market capitalisation: Danaher (DHR) $162.01B, Revvity (RVTY) $16.64B, Bio-Rad Laboratories (BIO) $9.64B.

Which stock is cheaper, DHR, RVTY and BIO?

Bio-Rad Laboratories (BIO) trades on the lowest price-to-earnings ratio (Danaher (DHR) 37.4x, Revvity (RVTY) 65.7x, Bio-Rad Laboratories (BIO) 9.4x). On next year's consensus earnings, Danaher (DHR) is cheapest (Danaher (DHR) 25.6x, Revvity (RVTY) 29.9x, Bio-Rad Laboratories (BIO) 36.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Danaher (DHR) grew revenue fastest over the trailing twelve months: Danaher (DHR) +5.5%, Revvity (RVTY) +4.6%, Bio-Rad Laboratories (BIO) +1.4%.

Which company is more profitable?

Bio-Rad Laboratories (BIO) has the highest net margin (Danaher (DHR) 16.9%, Revvity (RVTY) 8.6%, Bio-Rad Laboratories (BIO) 39.5%). On return on invested capital, Danaher (DHR) leads (Danaher (DHR) 5.8%, Revvity (RVTY) 3.3%, Bio-Rad Laboratories (BIO) -0.6%).

Which stock has performed better?

Over the past year Revvity (RVTY) returned the most: Danaher (DHR) +5.3%, Revvity (RVTY) +65.4%, Bio-Rad Laboratories (BIO) +15.5%. Over five years, Revvity (RVTY) compounded fastest (Danaher (DHR) -5.2%/yr, Revvity (RVTY) -3.4%/yr, Bio-Rad Laboratories (BIO) -13.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Danaher (DHR) 0.00%, Revvity (RVTY) 0.00%, Bio-Rad Laboratories (BIO) 0.00%. Danaher (DHR) and Bio-Rad Laboratories (BIO) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Danaher (DHR) 31.0%, Revvity (RVTY) 41.2%, Bio-Rad Laboratories (BIO) 36.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, DHR, RVTY and BIO?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Danaher (DHR) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.